Cancer testis antigens and immunotherapy: Where do we stand in the targeting of PRAME?

Ghaneya Al-Khadairi, Julie Decock

Research output: Contribution to journalReview article

Abstract

PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Although little is known about its pathophysiological function, PRAME has gained interest as a candidate target for immunotherapy. This review provides an update on our knowledge on PRAME expression and function in healthy and malignant cells and the current immunotherapeutic strategies targeting PRAME with their specific challenges and opportunities. We also highlight some of the features that position PRAME as a unique cancer testis antigen to target.

Original languageEnglish
Article number984
JournalCancers
Volume11
Issue number7
DOIs
Publication statusPublished - 1 Jul 2019

Fingerprint

Testicular Neoplasms
Immunotherapy
Antigens
Melanoma-Specific Antigens
Neoplasm Metastasis
Neoplasms

Keywords

  • Adoptive T cell therapy
  • Antibody
  • Cancer testis antigen
  • Cancer vaccine
  • Immunotherapy
  • PRAME

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cancer testis antigens and immunotherapy : Where do we stand in the targeting of PRAME? / Al-Khadairi, Ghaneya; Decock, Julie.

In: Cancers, Vol. 11, No. 7, 984, 01.07.2019.

Research output: Contribution to journalReview article

@article{408c5c6d2d654fbea3d061440add9fde,
title = "Cancer testis antigens and immunotherapy: Where do we stand in the targeting of PRAME?",
abstract = "PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Although little is known about its pathophysiological function, PRAME has gained interest as a candidate target for immunotherapy. This review provides an update on our knowledge on PRAME expression and function in healthy and malignant cells and the current immunotherapeutic strategies targeting PRAME with their specific challenges and opportunities. We also highlight some of the features that position PRAME as a unique cancer testis antigen to target.",
keywords = "Adoptive T cell therapy, Antibody, Cancer testis antigen, Cancer vaccine, Immunotherapy, PRAME",
author = "Ghaneya Al-Khadairi and Julie Decock",
year = "2019",
month = "7",
day = "1",
doi = "10.3390/cancers11070984",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

TY - JOUR

T1 - Cancer testis antigens and immunotherapy

T2 - Where do we stand in the targeting of PRAME?

AU - Al-Khadairi, Ghaneya

AU - Decock, Julie

PY - 2019/7/1

Y1 - 2019/7/1

N2 - PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Although little is known about its pathophysiological function, PRAME has gained interest as a candidate target for immunotherapy. This review provides an update on our knowledge on PRAME expression and function in healthy and malignant cells and the current immunotherapeutic strategies targeting PRAME with their specific challenges and opportunities. We also highlight some of the features that position PRAME as a unique cancer testis antigen to target.

AB - PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Although little is known about its pathophysiological function, PRAME has gained interest as a candidate target for immunotherapy. This review provides an update on our knowledge on PRAME expression and function in healthy and malignant cells and the current immunotherapeutic strategies targeting PRAME with their specific challenges and opportunities. We also highlight some of the features that position PRAME as a unique cancer testis antigen to target.

KW - Adoptive T cell therapy

KW - Antibody

KW - Cancer testis antigen

KW - Cancer vaccine

KW - Immunotherapy

KW - PRAME

UR - http://www.scopus.com/inward/record.url?scp=85071151349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071151349&partnerID=8YFLogxK

U2 - 10.3390/cancers11070984

DO - 10.3390/cancers11070984

M3 - Review article

AN - SCOPUS:85071151349

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 7

M1 - 984

ER -